MAVYRET is a fixed-dose combination of glecaprevir
a hepatitis C virus (HCV) NS3/4A protease inhibitor
and pibrentasvir
an HCV NS5A inhibitor
and is indicated for the treatment of adult and pediatric patients 3 years and older with chronic HCV genotype (GT) 1
2
3
4
5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A)
MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection
who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor
